Pharmacologic management of disease is performed for specific reasons, which include reducing symptoms, preventing disease progression, and preventing mortality. In arrhythmogenic cardiomyopathy (AC), there are no randomized clinical trial data on pharmacologic management, and little data overall on the use of drugs in this condition. This article discusses the role of pharmacology in AC to prevent symptoms, limit progression of disease, and prolong life.
- Antiarrhythmic agents
- Arrhythmogenic right ventricular cardiomyopathy/dysplasia
- Pharmacologic management
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)